RocRock Biotechnology

RocRock Biotechnology is a pioneering company in China specializing in macrophage drug therapy for solid tumors. Utilizing advanced gene editing, biomaterials, and synthetic biology, the company has developed four core technology platforms to address significant challenges in macrophage research and application. These platforms aim to overcome issues such as the difficulty and high cost of in vitro macrophage culture, long culture cycles, and challenges in macrophage gene transduction. RocRock Biotechnology serves the medical and pharmaceutical sectors, focusing on innovative treatments for cancer patients. The company operates in the biotechnology market and employs a business model centered around the development and clinical application of its proprietary technologies. Revenue is generated through partnerships, clinical trials, and eventual commercialization of its therapies.

Keywords: macrophage therapy, gene editing, synthetic biology, solid tumors, biotechnology, clinical application, cancer treatment, biomaterials, China, innovative platforms.